Related Experiment Video

Updated: Feb 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

Marc McGowan1, Lilach Kleinberg1,2, Ann Rita Halvorsen1

  • 1Department of Cancer Genetics, Radium Hospital - Oslo University Hospital, Oslo, Norway.

Genes & Cancer
|July 7, 2017
PubMed

Insights

Yes-associated protein (YAP) promotes cancer metastasis. This study found YAP overexpression or amplification in drug-resistant non-small cell lung cancer (NSCLC) cells, suggesting YAP as a therapeutic target for overcoming EGFR TKI resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Yes-associated protein (YAP) is a key downstream effector of the Hippo pathway.
  • YAP acts as an oncogene, promoting cancer progression and metastasis.
  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard treatments for non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the association between YAP expression and acquired resistance to EGFR TKIs in NSCLC.
  • To determine if YAP plays a role in the development of drug resistance in NSCLC.

Main Methods:

  • Utilized two NSCLC cell lines (HCC827 and H1975) engineered for resistance to erlotinib, gefitinib, or osimertinib.
  • Assessed YAP expression levels (overexpression and amplification) and subcellular localization.
  • Employed siRNA-mediated YAP silencing to evaluate its impact on drug sensitivity.

Main Results:

  • Acquired resistance to EGFR TKIs correlated with YAP overexpression or amplification.
  • YAP was found to be localized in the nucleus, indicating its active state.
  • Silencing YAP expression restored sensitivity to EGFR TKIs in resistant NSCLC cells (p < 0.05).

Conclusions:

  • YAP is implicated as a mechanism driving acquired resistance to EGFR TKIs in NSCLC.
  • Targeting YAP may represent a viable therapeutic strategy to overcome EGFR TKI resistance in NSCLC patients.
Keywords:
Drug-resistanceEGFREMTNSCLCYAP

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K